drugset / Trial / NCT00879827

Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants

NCT00879827

Phase 3 Completed 60 enrolled GlaxoSmithKline
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the immune response and reactogenicity of GSK Biologicals' DTPa-HBV-IPV combined pentavalent vaccine and Hib tetanus conjugate vaccine, administered concomitantly as a three-dose primary vaccination course.

Timeline

Start
2000-09
Primary completion
2001-05
Completion
2001-05

Drugs

EvaluationDrugModalityDoseRoute
Subject HAEMOPHILUS INFLUENZAE TYPE B STRAIN 20752 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN Vaccine
Subject Pediarix Vaccine